Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Special report
: The Fierce 50 of 2024
chronic pain
Pharma
Charles River to help Navega produce gene therapy candidate
Charles River is back with another gene therapy pact—this time centered on an AAV candidate tackling chronic pain in rare disease patients.
Fraiser Kansteiner
Mar 14, 2024 9:50am
AbbVie's Qulipta gains approval to prevent chronic migraines
Apr 18, 2023 3:20pm
Pacira finds knee pain hurts physically, socially and mentally
Nov 21, 2022 7:45am
Pain drug stigma stops patients from getting meds
Aug 5, 2022 11:14am
SciSparc unlocks nasal cannabinoid delivery via Polyrizon pact
May 31, 2022 10:10am
Consegna buys Fathom to expand long-acting injectable pipeline
Apr 22, 2022 7:17am
